Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 8, 2014, Pages 886-897

  Ono, Emiko ^a   Dutile, Stefanie ^a   Kazani, Shamsah ^a   Wechsler, Michael E ^a   Yang, Jun ^a   Hammock, Bruce D ^b   Douda, David Nobuhiro ^a   Tabet, Yacine ^c   Khaddaj Mallat, Rayan ^c   Sirois, Marco ^d   Sirois, Chantal ^d   Rizcallah, Edmond ^d   Rousseau, Éric ^c   Martin, Richard ^e   Sutherland, E R ^e   Castro, Mario ^f   Jarjour, Nizar N ^g   Israel, Elliot ^a   Levy, BruceD ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d UNIVERSITY OF SHERBROOKE   (Canada)

^e DEPARTMENT OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Asthma; Inflammation; Pro resolving mediators; Resolution

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 8 ISOPROSTANE; EPOXIDE HYDROLASE; LIPOXIN; STEROID; TERT BUTYL HYDROPEROXIDE; BIOLOGICAL MARKER; LIPOXIN A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOSYNTHESIS; BLOOD ANALYSIS; BRONCHUS; BRONCHUS REACTIVITY; CAUCASIAN; CELL INTERACTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ETHNICITY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; GENDER; HISPANIC; HUMAN; HUMAN TISSUE; LUNG LAVAGE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE; SPUTUM ANALYSIS; STEROID THERAPY; SUPERNATANT; THROMBOCYTE AGGREGATION; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPUTUM;

ADULT; ASTHMA; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; EPOXIDE HYDROLASES; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOXINS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922067239     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0544OC     Document Type: Article

References (42)

1. Fanta CH. Asthma. N Engl J Med 2009;360:1002-1014.
2. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, Chung KF, Curran-Everett D, Dweik RA, Fain SB, et al.; NHLBI Severe Asthma Research Program (SARP). Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185: 356-362.
3. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-268.
4. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, et al.; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-323.
5. Levy BD, Vachier I, Serhan CN. Resolution of inflammation in asthma. Clin Chest Med 2012;33:559-570.
6. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725.
7. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007;25:101-137.
8. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9:873-879.
9. Samuelsson B, Dahlé n SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-1176.
10. Lee TH, Crea AE, Gant V, Spur BW, Marron BE, Nicolaou KC, Reardon E, Brezinski M, Serhan CN. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis 1990;141:1453-1458.
11. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, Wechsler ME, Levy BD, Israel E. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 2013;132:547-553.
12. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E; Severe Asthma Research Program, National Heart, Lung, and Blood Institute. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005;172:824-830.
13. Vachier I, Bonnans C, Chavis C, Farce M, Godard P, Bousquet J, Chanez P. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005;115:55-60.
14. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002;8:1018-1023.
15. Christie PE, Spur BW, Lee TH. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992;145:1281-1284.
16. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol 2013;168:172-178.
17. Planagumá A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, Bleecker ER, Curran-Everett D, Erzurum SC, Calhoun WJ, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-582.
18. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005;102:2186-2191.
19. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer MA, Levy BD. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 2013;6:256-266.
20. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. Epoxyeicosatrienoic acid relaxing effects involve Ca2+-activated K+ channel activation and CPI-17 dephosphorylation in human bronchi. Am J Respir Cell Mol Biol 2007;36:633-641.
21. Zhang D, Xie X, Chen Y, Hammock BD, Kong W, Zhu Y. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Circ Res 2012;110:808-817.
22. Morin C, Sirois M, Echavé V, Albadine R, Rousseau E. 17,18-Epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol 2010;43:564-575.
23. Planagumà A, Pfeffer MA, Rubin G, Croze R, Uddin M, Serhan CN, Levy BD. Lovastatin decreases acute mucosal inflammation via 15-epilipoxin A4. Mucosal Immunol 2010;3:270-279.
24. Morisseau C, Hammock BD. Measurement of soluble epoxide hydrolase (SEH) activity. Current Protoc Toxicol 2007;33:4.23.1-4.23.18.
25. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, Castells MC, Chhay H, Boyce JA. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012;119:3790-3798.
26. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009;119:3450-3461.
27. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006;116:3211-3219.
28. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 2008;38:192-201.
29. Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001;158:3-9.
30. Dworski R, Murray JJ, Roberts LJ II, Oates JA, Morrow JD, Fisher L, Sheller JR. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med 1999;160:1947-1951.
31. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, et al.; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-548.
32. Wood LG, Garg ML, Simpson JL, Mori TA, Croft KD, Wark PA, Gibson PG. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005;171:426-430.
33. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990;172:1451-1457.
34. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010;48:331-341.
35. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002;63:1599-1608.
36. Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem 2010;53:7067-7075.
37. Lee KS, Morisseau C, Yang J, Wang P, Hwang SH, Hammock BD. Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase. Anal Biochem 2013;434:259-268.
38. Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, Giannini S, Momi S, Spina D, O'connor B, et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003;112:109-118.
39. Gresele P, Dottorini M, Selli ML, Iannacci L, Canino S, Todisco T, Romano S, Crook P, Page CP, Nenci GG. Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. J Allergy Clin Immunol 1993;91:894-902.
40. Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets 2007;18:319-328.
41. Kowal K, Pampuch A, Kowal-Bielecka O, DuBuske LM, Bodzenta-Łukaszyk A. Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy 2006;36:426-432.
42. Yost CC, Weyrich AS, Zimmerman GA. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010;92:692-697.